Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Antibiotic Administration in PCNL
NCT02579161Phase 3Completed
- Sponsor
- Northwell Health
- Start
- Sep 2014
- Primary completion
- Mar 2018
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefazolin in nephrolithiasis (2 arms), sponsored by Northwell Health. Primary endpoint: Number of Participants With Infectious Complications. Started Sep 2014; status: completed.
02
Drugs
cefazolin
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on NCT02579161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579161.